AstraZeneca failed to provide sufficient data from its studies. Credit: PublicDomainPictures on Pixabay.

The Peruvian government has refused to sign an agreement with to purchase coronavirus vaccine as the latter failed to provide sufficient data from its studies.

The company is also believed to have offered minimal amounts of inoculations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Reuters quoted Peru Prime Minister Walter Martos as saying in a news conference that the government sought data from AstraZeneca鈥檚 vaccine studies, but the company had not sent the information.

Martos added: 鈥淭he other labs have caught up with us accordingly, however, AstraZeneca has not.

鈥淭hey were offering us a very low quantity of vaccines compared with other laboratories that are offering us large quantities at lower costs.鈥�

Even though Peru is witnessing a decrease in the number of new infections, a second wave of the pandemic is possible, Martos said.

The rate of infections and deaths from Covid-19 in Peru has been slowing since September. As of 20 October, the total number of cases reported was 876,885, with 33,937 deaths.

In September, Peru鈥檚聽National Health Institute (INS)聽authorised AstraZeneca to carry out phase III clinical trials of its candidate vaccine against Covid-19 on approximately 3,000 volunteers in the country.

AstraZeneca also signed a vaccine supply deal with many countries including the US, UK, Australia, China, Brazil and the European Union (EU) Member States.

Moreover, in July, the company put a voluntary hold on its trial of the vaccine candidate after a participant fell ill. It said that the patient had an undiagnosed case of multiple sclerosis and the illness was unrelated to the vaccine.